Marginal Zone Lymphoma: Treatment Challenges & Options

For patients facing a return of marginal zone lymphoma (MZL) – a type of slow-growing blood cancer – or those who don’t respond to initial treatments, new options are emerging. While standard approaches like anti-CD20 therapies, lenalidomide in combination with rituximab, and Bruton tyrosine kinase inhibitors (BTKis) are used, achieving lasting remission can be difficult. Recent attention has turned to CAR T-cell therapy as a potential breakthrough for this challenging condition.

Marginal zone lymphoma accounts for roughly 7% of all non-Hodgkin lymphomas, characterized by its varied presentation across different areas of the body – the lymph nodes, the spleen, or in tissues like the mucosa. Research published in The Lancet highlights the require for more effective treatments for those whose MZL returns or proves resistant to conventional therapies.

Understanding CAR T-cell Therapy

CAR T-cell therapy is a personalized form of immunotherapy. It involves collecting a patient’s own T-cells – a type of immune cell – and genetically engineering them to express a chimeric antigen receptor (CAR). This CAR allows the T-cells to recognize and attack cancer cells displaying a specific protein on their surface. The modified T-cells are then infused back into the patient, where they seek out and destroy the lymphoma cells.

While CAR T-cell therapy has shown remarkable success in certain blood cancers like leukemia and aggressive lymphoma, its application to indolent lymphomas like MZL is relatively new and still under investigation. The Frontiers in Oncology journal notes that while patients with MZL generally have a longer survival period, around 20% experience relapse or grow refractory to treatment, creating a need for innovative approaches.

Current Treatment Landscape for Relapsed/Refractory MZL

Before considering CAR T-cell therapy, patients with relapsed or refractory MZL typically undergo treatment with anti-CD20-based regimens. These therapies target a protein called CD20 found on the surface of B-cells, including the cancerous ones. Lenalidomide-rituximab combinations, utilizing the drug lenalidomide alongside the antibody rituximab, are also common. More recently, Bruton tyrosine kinase inhibitors (BTKis) have emerged as options, blocking a key signaling pathway involved in B-cell growth and survival.

However, these treatments don’t always provide long-lasting benefits. The challenge lies in the ability of the lymphoma to develop resistance or return after initial remission. This represents where CAR T-cell therapy offers a potentially different mechanism of action, harnessing the patient’s own immune system to target the cancer.

What the Evidence Shows So Far

The research surrounding CAR T-cell therapy for MZL is still evolving. While early clinical trials have demonstrated promising results, it’s crucial to understand the limitations. The initial studies often involve modest numbers of patients, making it difficult to draw definitive conclusions. The long-term effects of CAR T-cell therapy – including the duration of remission and potential side effects – are still being monitored.

The Lancet article doesn’t detail specific trial results, but emphasizes the need for further investigation. It’s important to note that CAR T-cell therapy is not without risks. Potential side effects can include cytokine release syndrome (CRS), a systemic inflammatory response, and neurotoxicity, affecting the nervous system. These side effects require careful monitoring and management by experienced medical teams.

Lenalidomide and Rituximab: A Continued Role

Alongside the exploration of CAR T-cell therapy, existing treatments continue to play a vital role in managing MZL. Revlimid (lenalidomide), in combination with a rituximab product, is approved for adults with follicular lymphoma or marginal zone lymphoma who have previously been treated. This combination targets and destroys the cancerous B-cells, offering a valuable option for those who have experienced relapse or refractoriness.

What Comes Next: Ongoing Research and Clinical Trials

The future of MZL treatment hinges on continued research and clinical trials. Researchers are actively investigating ways to improve the efficacy and safety of CAR T-cell therapy, including optimizing the CAR design, refining the conditioning regimen (the chemotherapy given before T-cell infusion), and developing strategies to manage potential side effects.

Further studies are needed to identify which patients are most likely to benefit from CAR T-cell therapy and to determine the optimal timing of treatment. Clinical trials are essential for gathering the data needed to establish CAR T-cell therapy as a standard treatment option for relapsed or refractory MZL. Patients interested in participating in clinical trials should discuss the possibilities with their oncologist.

For individuals diagnosed with MZL, staying informed about the latest advancements and maintaining open communication with their healthcare team is paramount. While CAR T-cell therapy represents a promising avenue for treatment, it’s essential to approach it with realistic expectations and a thorough understanding of the potential benefits and risks.